SDSerkan Demir

Serkan Demir

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Serkan Demir has a total of 217 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Exploring the Type 4 Cerebrospinal Fluid Oligoclonal Band Pattern: Clinical and Paraclinical Features with Diagnostic Implications

    by Duygu Arslan Mehdiyev, Meryem Tuba Sönmez, Sedat Şen, Sümeyye Koç, Gökhan Arslan, Nur Yüceyar, Furkan Sarıdaş, Emine Rabia Koç, Ömer Faruk Turan, İrem Taşcı, et al.

  • Open Access

    Clinical Impact of Fingolimod-Associated Lymphopenia in Multiple Sclerosis: A Real-World Cohort Study

    by Murat Yeniçeri, Mustafa Can Şenoymak, Süleyman Baş, Hasan Hakan Çoban, Ayşe Gürbüz Yeniçeri, Serkan Demir, Alpaslan Tanoglu

    Background and Objectives: Fingolimod, a sphingosine-1-phosphate receptor modulator, is an effective disease-modifying therapy for relapsing forms of multiple sclerosis (MS). Although lymphopenia is a well-recognized pharmacological effect, its clinical significance remains uncertain. This study evaluated the frequency and severity of fingolimod-associated lymphopenia, longitudinal hematological changes and their relationship with clinical outcomes in a real-world MS cohort. Materials and Methods: This retrospective observational study included 143 adults with MS who initiated fingolimod treatment between May 2019 and October 2020. Demographic, clinical and laboratory data were collected at baseline and at 3- and 6-month follow-up visits. Lymphopenia was graded according to the Common Terminology Criteria for Adverse Events version 4.0. Laboratory parameters and infection outcomes were compared according to lymphopenia severity. Logistic regression analysis was performed to identify factors associated with Grade 4 lymphopenia at 6 months. Results: At 6 months, lymphopenia was present in 124 patients (86.7%), including Grade 4 lymphopenia in 15 (10.5%). Leukocyte, neutrophil and lymphocyte counts decreased, whereas ALT, AST, GGT, NLR and SII increased significantly during treatment (all p < 0.001). Infection frequency did not differ among lymphopenia severity groups (p = 0.530). No statistically significant association was detected between Grade 3–4 lymphopenia and infection risk (OR, 1.41; 95% CI, 0.42–4.71; p = 0.545). Lower baseline lymphocyte count was independently associated with Grade 4 lymphopenia (adjusted OR 0.078, 95% CI 0.018–0.325; p < 0.001). Conclusions: Fingolimod-associated lymphopenia was common, with Grade 4 lymphopenia affecting approximately one-tenth of patients. No statistically significant association between lymphopenia severity and infection was detected; however, the small number of Grade 4 cases, low event rate and wide confidence interval limited the statistical power to exclude clinically meaningful differences. These findings should therefore be interpreted cautiously and do not establish the absence of infection risk associated with severe lymphopenia. Regular hematological monitoring and individualized clinical decision-making remain essential, particularly in patients with lower baseline lymphocyte counts.


  • Open Access

    Respiratory Muscle Performance and Pulmonary Function in Sarcopenic and Non-Sarcopenic Patients with Multiple Sclerosis: A Cross-Sectional Study

    by Tuba Kolayli Çerezci, Filiz Eyüboğlu, Şahika Ocak, Serkan Demir, Sibel Aksu Yıldırım

    Background: Respiratory muscle dysfunction is a recognized complication of multiple sclerosis (MS) and may contribute to functional decline. Sarcopenia related to neurological impairment may further impair respiratory muscle performance in MS. This study aimed to investigate the association between sarcopenia and respiratory function, respiratory muscle strength, and respiratory muscle endurance in patients with MS. Methods: This study was designed as a cross-sectional observational study. In this study, 52 MS patients (26 sarcopenic, 26 non-sarcopenic) were evaluated. Sarcopenia was assessed using the SARC-F questionnaire, handgrip strength, bioelectrical impedance analysis, calf circumference, and walking speed (6-m walk test). Pulmonary function was evaluated using spirometry. Respiratory muscle strength was assessed using maximal inspiratory and expiratory pressures (MIP, MEP), and respiratory muscle endurance was evaluated using a constant-load test. Results: Respiratory muscle endurance (p < 0.001), inspiratory volume (p < 0.001), and forced vital capacity (p = 0.003) were significantly lower in sarcopenic MS patients in the primary analyses. However, inspiratory volume and respiratory muscle endurance remained significant after age adjustment, while all three parameters remained significant after EDSS adjustment. No significant differences were observed between groups in other respiratory function parameters or respiratory muscle strength including MIP, and MEP (p > 0.05). Conclusions: Sarcopenia is associated with reduced respiratory muscle endurance and respiratory capacity in patients with MS. These findings suggest that respiratory muscle endurance assessment may help identify sarcopenic MS patients who warrant further respiratory evaluation. Incorporating respiratory muscle endurance assessment into routine evaluation and rehabilitation strategies may be beneficial in sarcopenic MS patients.

  • Beyond serology: clinical and prognostic determinants in patients with dual AQP4-IgG and MOG-IgG seropositivity

    by Ipek Gungor Dogan, Sedat Sen, Damla Cetinkaya Tezer, Sude Kendirli Aslan, Haluk Gumus, Bilge Piri Cinar, Nuray Bilge, Ozlem Ethemoglu, Ferah Kizilay, Cavit Boz, et al.

  • Open Access

    Real-world effectiveness and safety of eculizumab in AQP4-IgG-positive neuromyelitis optica spectrum disorder

    by Emine Rabia Koc, Mehmet Fatih Yetkin, Furkan Saridas, Omer Faruk Turan, Serhan Sevim, Murat Terzi, Sedat Sen, Melih Tutuncu, Ugur Uygunoglu, Murat Kurtuncu, et al.

    Objective: To evaluate the real-world effectiveness and safety of eculizumab in patients with AQP4-IgG–positive neuromyelitis optica spectrum disorder (NMOSD) and to identify predictors of disability outcomes. Methods: This multinational, retrospective cohort study analyzed data from 46 patients across 26 centers. The outcomes included the annualized relapse rate (ARR), relapse-free status, change in expanded disability status scale (EDSS) scores, and adverse events. To identify predictors of EDSS improvement or worsening, patients were stratified into subgroups (improved vs. stable/worsened) at each follow-up time point and compared based on demographic, clinical, and radiological variables. Results: This retrospective cohort study included 46 patients with AQP4-IgG-positive NMOSD from 26 centers, followed for a mean of 27.3 months. The mean ARR significantly decreased from 1.1 in the 2 years pre-treatment to 0.1 during eculizumab therapy. The relapse-free rate increased from 6.5% pre-treatment to 80.4%. Mean EDSS scores improved from 4.2 at baseline to 3.6 at 24 months. The presence of area postrema syndrome was associated with a favorable prognosis, while the presence of spinal attacks was associated with a poor prognosis at 12 months. Adverse events occurred in 7 patients (18.9%), leading to permanent discontinuation in only two. Conclusion: Eculizumab demonstrated robust real-world effectiveness in reducing relapse rates and stabilizing disability, with an acceptable safety profile. Clinical outcomes may be influenced by attack phenotype, underscoring the importance of early intervention.


  • Differential Metacognitive Profiles in Relapsing–Remitting and Progressive Multiple Sclerosis: Associations with Fatigue, Cognition, and Perceived Disability

    by Ozlem Totuk, Merve Turkkol, Hasan Can Gudek, Ipek Gungor Dogan, Damla Cetinkaya Tezer, Sevki Sahin, Serkan Demir

    Objective: This study examined metacognitive belief profiles in individuals with multiple sclerosis (MS) and their associations with cognitive, emotional, and functional outcomes. Specifically, we compared relapsing–remitting MS (RRMS), secondary progressive MS (SPMS), and primary progressive MS (PPMS) to determine whether distinct metacognitive patterns characterize different disease phenotypes. Method: A total of 504 participants (75.6% RRMS, 9.9% SPMS, 14.5% PPMS) were recruited from a neurology clinic. Participants completed the Metacognitions Questionnaire-30 (MCQ-30), Montreal Cognitive Assessment (MoCA), Beck Depression Inventory (BDI), Modified Fatigue Impact Scale (MFIS), Expanded Disability Status Scale (EDSS), Short Form-12 (SF-12), and Occupational Self-Assessment (OSA). Group differences were examined using ANOVA, correlations via Pearson coefficients, and hierarchical and ordinal regression models. Results: Progressive phenotypes, particularly PPMS, showed significantly higher maladaptive metacognitive beliefs than RRMS. RRMS individuals exhibited greater cognitive self-consciousness and need for control, whereas PPMS was associated with lower cognitive confidence and stronger negative beliefs about uncontrollability. No subtype differences emerged in positive beliefs. Maladaptive metacognition correlated with lower cognitive performance, greater fatigue, depressive symptoms, reduced quality of life, and lower self-efficacy. In regression models, depression was the strongest negative predictor of self-efficacy, while cognitive self-consciousness was a positive predictor. Clinical and psychological variables together explained 60% of the variance in self-efficacy. Metacognitive beliefs and fatigue also predicted higher neurological disability (EDSS). Conclusions: Metacognitive belief patterns differ across MS phenotypes and significantly impact both functional and neurological outcomes. These findings support incorporating metacognitive assessment into routine MS care and underscore the need for tailored psychological interventions addressing cognitive-emotional regulation.

  • Is there a role of MOG antibodies in idiopathic intracranial hypertension: A comparative analysis with optic neuritis-MOG antibody associated disease

    by Guldeniz Cetin Erci, Tugba Gencaga Atakan, Mesut Yigit, Ozlem Gulacti, Sibel Balci, Hasan Can Gudek, Damla Cetinkaya Tezer, Ipek Gungor Dogan, Serkan Demir

  • Open Access

    Sexual dysfunction in multiple sclerosis: prevalence, risk factors, and impact on quality of life in a large cohort study

    by Ozlem Totuk, Merve Türkkol, Feyzullah Yadi, Hasan Can Güdek, Güldeniz Çetin Erci, İpek Güngör Doğan, Damla Çetinkaya Tezer, Sevki Sahin, Serkan Demir

    Sexual dysfunction (SD) is a prevalent but underreported symptom in people with multiple sclerosis (pwMS), significantly affecting quality of life (QoL). Despite its clinical relevance, SD is often overlooked during routine care. This study aimed to determine the prevalence of SD, identify associated risk factors, assess its impact on depression and QoL, and explore help-seeking behaviors among pwMS. A cross-sectional study was conducted with 504 pwMS followed at a tertiary MS clinic between November 2023 and May 2024. Data on demographics, disease characteristics, and medications were collected. The Arizona Sexual Experiences Scale (ASEX) was used to assess SD, the Beck Depression Inventory (BDI) for depression, and the Short Form-12 (SF-12) for QoL. EDSS scores were used to evaluate disability. Statistical analyses included t-tests, ANOVA, chi-square, correlation analyses, and univariate and multivariate logistic regression, with significance set at p < 0.05. SD was identified in 69.0% of patients (73.9% of women, 57.6% of men). SD was significantly associated with female gender (p = 0.001), older age (p = 0.006), higher EDSS scores (p = 0.046), and increased depression levels (r = 0.38). SF-12 scores were significantly lower among those with SD (p < 0.001). In multivariate analysis, female gender (aOR = 2.01, p = 0.002) and higher BDI scores (aOR = 1.09, p < 0.001) remained independently associated with SD, while age and EDSS did not. No significant associations were found between SD and MS type, disease duration, or type of disease-modifying therapy. Only 9.8% of patients with SD sought medical help, while 83.1% did not seek support. SD is highly prevalent among pwMS and is closely linked to age, disability, depression, and reduced QoL. Depression emerged as a strong independent predictor. Despite this burden, most patients do not seek help. Multidisciplinary approaches and routine screening are essential to address SD in clinical settings.


  • Open Access

    Comparative prognostic value of inflammatory and nutritional indices in acute ischemic stroke: a multivariable model analysis

    by İrEm Kıraç Utku, Nazire Çelem, Serkan Demir, Ahmet Düzgün

    Aims: Given that acute ischemic stroke (AIS) is a leading cause of mortality and long-term disability, the early identification of reliable prognostic markers is essential. This study evaluates the prognostic value of composite inflammatory and nutritional indices, including the monocyte-to-high-density lipoprotein cholesterol ratio (MHR), Systemic Immune-Inflammation Index (SII), Prognostic Nutritional Index (PNI), and Controlling Nutritional Status (CONUT) score, in predicting intensive care unit (ICU) admission and one-year mortality following AIS. Methods: This single-center retrospective cohort study included 496 patients with a confirmed diagnosis of AIS. Clinical characteristics, laboratory parameters, and outcomes were retrospectively retrieved. The prognostic significance of selected inflammatory indices [MHR, SII, neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and platelet-to-lymphocyte ratio (PLR)] and nutritional indices (PNI and CONUT) was analyzed using univariate and multivariate logistic regression models, along with receiver operating characteristic (ROC) curve analysis. Results: Higher SII and CONUT scores and lower PNI values were significantly associated with both ICU admission and one-year mortality. In multivariate analysis, CONUT and MHR emerged as independent predictors of one-year mortality, while PNI, CONUT, and MHR independently predicted ICU admission. Among all indices evaluated, CONUT demonstrated the highest predictive accuracy for both outcomes. Conclusion: In patients with AIS, composite inflammatory and nutritional indices-particularly CONUT and MHR-provided valuable prognostic information. These markers, derived from routine laboratory tests, offer a practical and cost-effective method for early risk stratification and may help guide more personalized care pathways in stroke management.

  • The prevalence and clinical significance of trigeminal neuralgia in patients with multiple sclerosis

    by İpek Güngör Doğan, Ebru Kaya, Sude Kendirli Aslan, Damla Çetinkaya Tezer, Serkan Demir

    Background & Objective: Trigeminal neuralgia (TN) is a debilitating neuropathic pain disorder characterized by sudden and intense episodes of facial pain, significantly impairing patients’ quality of life. Diagnosing TN is particularly challenging in multiple sclerosis (MS), a chronic autoimmune, demyelinating, and neurodegenerative disease affecting the central nervous system. TN in MS is predominantly caused by demyelination, axonal loss, inflammation, and brainstem lesions. However, the overlapping symptoms of TN and other craniofacial pain disorders often lead to underdiagnosis and treatment delays. This study aimed to determine the prevalence and clinical characteristics of TN in MS patients, in a cohort of Turkish patients, with a focus on diagnostic challenges and treatment patterns. Methods: A single-center, cross-sectional survey was conducted, systematically assessing headache and facial pain symptoms among MS patients treated at the Sancaktepe Neuroimmunology Clinic, Istanbul, Turkey. Results: The findings revealed a significant prevalence of TN (39.8%) in MS patients, with a female predominance and a mean diagnostic delay of 14 months. Despite the availability of effective treatments, a substantial proportion of patients remained undiagnosed and untreated. Conclusion: There is urgent need to integrate routine TN screening into MS patient care to improve timely diagnosis and effective management. The study underscores the importance of a multidisciplinary approach in addressing this overlooked comorbidity, ultimately enhancing the quality of life for MS patients.